Nanobiotix SA

2,9950

14-апреля-25 11:21:13

15 мин. задержка

Акции

+0,0625

+2,13%

Сегодняшний диапазон

2,9700 - 3,0350

ISIN

FR0011341205

Источник

Cboe

Voting Rights and Shares Capital of the Company

08 авг 2024 16:15:00 Источник Nasdaq GlobeNewswire
Voting Rights and Shares Capital of the Company

09 июл 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

12 июн 2024 16:15:00 Источник Nasdaq GlobeNewswire
Voting Rights and Shares Capital of the Company

11 июн 2024 16:15:00 Источник Nasdaq GlobeNewswire
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

02 июн 2024 10:00:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

28 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

23 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22 май 2024 02:00:00 Источник Nasdaq GlobeNewswire
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

21 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
Voting Rights and Shares Capital of the Company

16 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

15 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

14 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

24 апр 2024 16:40:39 Источник Nasdaq GlobeNewswire
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

17 апр 2024 16:15:00 Источник Nasdaq GlobeNewswire
Voting Rights and Shares Capital of the Company

10 апр 2024 16:15:00 Источник Nasdaq GlobeNewswire
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02 апр 2024 16:15:00 Источник Nasdaq GlobeNewswire
Nanobiotix to Present at Upcoming Investor Conferences in March

06 мар 2024 16:15:00 Источник Nasdaq GlobeNewswire
Voting Rights and Shares Capital of the Company

13 фев 2024 16:15:00 Источник Nasdaq GlobeNewswire
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

31 янв 2024 16:15:00 Источник Nasdaq GlobeNewswire
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

29 янв 2024 16:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.